LEMS and Cancer: The Search for a Hidden Trigger

For about 50% to 60% of people diagnosed with Lambert-Eaton Myasthenic Syndrome (LEMS), the condition is paraneoplastic ^[1][2]. This means the immune system’s attack on your nerves was actually triggered by an underlying cancer, most commonly Small Cell Lung Cancer (SCLC) ^[1][3].

Because LEMS symptoms—like leg weakness—often appear months or even years before a tumor is large enough to cause traditional cancer symptoms, LEMS can act as a critical early warning system ^[4][5]. In some cases, this allows doctors to detect the cancer earlier than is typical. However, it is vital to understand that an earlier detection does not guarantee a cure; SCLC remains a serious and aggressive cancer, and a patient’s prognosis is driven primarily by the cancer’s stage, tumor biology, and response to treatment, rather than by the presence of LEMS alone ^[2][6].

Assessing Your Risk: The DELTA-P Score

To help estimate how likely it is that a patient’s LEMS is related to a hidden tumor, clinicians often use a validated risk-stratification tool such as the DELTA-P score (Dutch-English LEMS Tumor Association Prediction score) ^[1].

This clinical tool uses six specific variables (each assigned 1 point) present at or near the time of diagnosis to estimate SCLC risk:

1. Age: Being 50 years of age or older.
2. Smoking History: Being a current or former smoker.
3. Weight Loss: Unintentional weight loss of 5% or more.
4. Bulbar Involvement: Symptoms involving swallowing, chewing, or speech.
5. Erectile Dysfunction: (in men).
6. Performance Status: A Karnofsky Performance Status of less than 70 (indicating significant difficulty with daily activities).

Important: This score estimates risk but never replaces actual chest imaging. It must be calculated by your clinician and interpreted in the context of your overall health. Even with a low score, screening is still required.

The Vigilance Phase: Screening and Surveillance

If your initial scans are negative, it does not mean you are “in the clear.” SCLC can be extremely small and “occult” (hidden) for a long time ^[7][5]. Current guidelines (such as European or disease-specific consensus panels) recommend a rigorous, risk-adapted surveillance schedule to catch any emerging tumor:

• Initial Screen: A chest CT scan with contrast. If the clinical risk is high or findings are ambiguous, a PET/CT scan may be used appropriately by your clinician ^[8][7]. (PET/CT is not automatic for every patient.)
• The Highest-Risk Window (Years 1-2): If the first scan is clear, clinicians typically repeat the screening at a directed range, often at 3 to 6 months, and then every 6 months until you have reached the 2-year mark since your LEMS diagnosis ^[9][10].
• Ongoing Monitoring: After two years, the risk of finding a new SCLC drops significantly, but rare cases have been found 5 to 9 years later ^[7][5]. Clinicians often continue periodic surveillance (sometimes annually) for additional years based on your individualized risk profile.

Managing the Search

The “waiting and watching” period can be emotionally exhausting—a feeling often called “scan anxiety.”

• Coordinated Care: If cancer is found, the priority becomes a coordinated approach: oncology will treat the cancer (which often significantly improves the LEMS symptoms), while neurology concurrently manages your weakness and breathing with LEMS-specific medications ^[4][9].
• Survival Perspectives: Some observational studies report that LEMS patients who have SCLC may have better outcomes than SCLC patients without LEMS, likely due to earlier detection and immune activity ^[6][11]. However, as noted, outcomes remain highly dependent on the cancer’s stage and treatment success.

If you notice new symptoms like a persistent cough, chest pain, or coughing up blood, you should contact your doctor immediately rather than waiting for your next scheduled scan ^[8].